Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

The primary objective is to demonstrate, in systemic treatment-naïve patients with moderate to severe plaque psoriasis, that the cumulative effect of treatment with secukinumab 300 mg over 32 weeks, as measured by the area under the curve (AUC) for PASI percent change from baseline, is superior to that seen with a standard treatment pathway.

Critère d'inclusion

Moderate to Severe Plaque Psoriasis

Liens

euctr